Status:
COMPLETED
Intravitreal Infliximab for Proliferative Vitreoretinopathy
Lead Sponsor:
Cairo University
Conditions:
Rhegmatogenous Retinal Detachment
Proliferative Vitreoretinopathy
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Proliferative vitreoretinopathy (PVR) is the most common cause for failure of rhegmatogenous retinal detachment repair and is characterized by the growth and contraction of cellular membranes within t...
Detailed Description
Proliferative vitreoretinopathy (PVR) is the most common cause for failure of rhegmatogenous retinal detachment repair and is characterized by the growth and contraction of cellular membranes within t...
Eligibility Criteria
Inclusion
- Age: more than or equal to 18 years
- Primary rhegmatogenous retinal detachment with proliferative vitreoretinopathy more than or equal to grade C
Exclusion
- Patients with a history of open globe injury
- Recurrent retinal detachment or primary failed retinal detachment surgery
- History of vitreoretinal procedure
- Retinal vascular diseases (Diabetic retinopathy, retinal vein occlusion,...etc)
- Pregnant or breastfeeding females
- Inability to attend regular follow-up visits
- History of pulmonary or extra-pulmonary tuberculosis.
Key Trial Info
Start Date :
November 26 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 10 2023
Estimated Enrollment :
66 Patients enrolled
Trial Details
Trial ID
NCT04891991
Start Date
November 26 2021
End Date
November 10 2023
Last Update
January 19 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cairo University
Cairo, Egypt, 11956